Tyra Biosciences (NASDAQ:TYRA - Get Free Report) had its price objective dropped by equities researchers at HC Wainwright from $29.00 to $27.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 28.57% from the company's previous close.
Several other analysts have also commented on TYRA. Weiss Ratings reissued a "sell (d-)" rating on shares of Tyra Biosciences in a research note on Thursday, October 15th. William Blair upgraded shares of Tyra Biosciences to a "strong-buy" rating in a research report on Wednesday, September 23rd. Oppenheimer restated an "outperform" rating and issued a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday, September 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Finally, Wedbush reiterated an "outperform" rating and set a $53.00 price objective on shares of Tyra Biosciences in a research report on Thursday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $47.00.
Check Out Our Latest Stock Report on Tyra Biosciences
Tyra Biosciences Trading Down 5.8%
NASDAQ:TYRA opened at $21.00 on Wednesday. Tyra Biosciences has a twelve month low of $13.83 and a twelve month high of $40.65. The company has a 50-day moving average of $22.04 and a 200-day moving average of $29.54. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -8.75 and a beta of 0.65.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07). On average, research analysts forecast that Tyra Biosciences will post -2.68 earnings per share for the current year.
Institutional Trading of Tyra Biosciences
A number of hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. increased its position in shares of Tyra Biosciences by 31.4% in the third quarter. Alps Advisors Inc. now owns 79,051 shares of the company's stock worth $1,729,000 after acquiring an additional 18,892 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Tyra Biosciences in the 3rd quarter valued at approximately $67,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Tyra Biosciences by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,889 shares of the company's stock valued at $239,000 after acquiring an additional 1,424 shares in the last quarter. Sterling Capital Management LLC boosted its stake in Tyra Biosciences by 843.4% in the 3rd quarter. Sterling Capital Management LLC now owns 1,217 shares of the company's stock worth $27,000 after purchasing an additional 1,088 shares during the period. Finally, Tidal Investments LLC acquired a new position in Tyra Biosciences in the 2nd quarter worth approximately $943,000. 84.14% of the stock is owned by hedge funds and other institutional investors.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company's pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.